Company: RGNT
Filing Date: 2025-07-07
Form Type: F-1/A
Source: 0001213900-25-061821
Chunk: 72

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-07-07
Form: F-1/A
Chunk 72
---
subject to extreme volatility that is seemingly unrelated to the underlying performance of our business. Recently, companies with comparable
anticipated public floats and initial public offering sizes have experienced instances of extreme stock price run-ups followed by rapid
price declines, and such stock price volatility was seemingly unrelated to the respective company’s underlying performance. Although
the specific cause of such volatility is unclear, our anticipated public float may amplify the impact of the actions taken by a few shareholders
on the price of our Ordinary Shares, which may cause our share price to deviate, potentially significantly, from a price that better
reflects the underlying performance of our business. Should our Ordinary Shares experience run-ups and declines that are seemingly unrelated
to our actual or expected operating performance and financial condition or prospects, prospective investors may have difficulty assessing
the rapidly changing value of our Ordinary Shares. In addition, investors of shares of our Ordinary Shares may experience losses, which
may be material, if the price of our Ordinary Shares declines after this offering or if such investors purchase shares of our Ordinary
Shares prior to any price decline.

<div align='center'>47</div>

If our operating and financial performance in any given period does not meet any guidance that we provide to the public, the market price of our Ordinary Shares may decline.

We may, but are not obligated
to, provide public guidance on our expected operating and financial results for future periods. Any such guidance will be comprised of
forward-looking statements subject to the risks and uncertainties described in this prospectus and in our other public filings and public
statements. Our actual results may not always be in line with or exceed any guidance we have provided, especially in times of economic
uncertainty. If, in the future, our operating or financial results for a particular period do not meet any guidance we provide or the
expectations of investment analysts, or if we reduce our guidance for future periods, the market price of our Ordinary Shares may decline.
Even if we do issue public guidance, there can be no assurance that we will continue to do so in the future.

If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our shares, the price of our shares could decline.

The trading market for our
securities will rely in part on the research and reports that industry or financial analysts publish about us or our business. We do
not currently have and may never obtain research coverage by industry or financial analysts. If no or few analysts commence coverage
of us, the trading price of our shares could